New drug combo tested in fight against Fast-Growing lymphoma
NCT ID NCT04850495
Summary
This early-phase trial is testing whether adding an experimental drug called zanubrutinib to standard chemotherapy is safe and tolerable for adults newly diagnosed with an aggressive type of blood cancer called diffuse large B-cell lymphoma. The main goal is to find the best dose of zanubrutinib to use with the standard drugs and to understand the side effects. Researchers will also track how well the combination works to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
MUSC
Charleston, South Carolina, 29425, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.